You are here: Home » Current Affairs » Coronavirus » News
Business Standard

ICMR, Biological E Ltd develop potential treatment for coronavirus

The ICMR in collaboration with a Hyderabad-based biopharmaceutical company has developed "highly purified antisera" prepared by injecting inactivated SARS-CoV2 in horses

Topics
Coronavirus | Coronavirus Vaccine | Coronavirus Tests

Press Trust of India  |  New Delhi 

Coronavirus, vaccine, tests, covid, drugs, clinical trials
Representative image

The in collaboration with a Hyderabad-based biopharmaceutical company has developed "highly purified antisera" prepared by injecting inactivated SARS-CoV2 in horses, which can be a potential treatment for COVID-19.

"The and Biological E Limited, Hyderabad, have developed highly purified antisera (raised in animals) for prophylaxis and treatment of COVID-19," the apex health research body said on Thursday.

The 'antisera' is yet to undergo human clinical trials to establish its safety and efficacy and Drugs Controller General of India would be approached soon in this regard, Dr Samiran Panda, the head of epidemiology and communicable diseases at the Indian Council of Medical Research (ICMR) said.

Antisera are blood serum high in antibodies against specific antigens and are injected in humans to help kickstart the immune system to fight specific infections.

The pre-print version of the study regarding the development of the equine antisera has been posted on Research Square platform.

"The study provides evidence of the potential of generating highly purified F(ab')2 from equines against SARS-CoV-2 that can demonstrate consistent and high neutralization activity. Further, in-vivo testing for efficacy of this indigenously developed, cost effective product will pave the way to clinical evaluation. Additionally, being a donor independent method, this may prove as an efficient alternative to convalescent plasma for treatment of COVID-19 patients," the study paper said.

Earlier such measures were used for controlling several viral and bacterial infections.

"Although, plasma recovered from patients experiencing COVID-19 could serve similar purpose, the profile of antibodies, their efficacy and concentration keep varying from one patient to another and therefore make it an unreliable clinical tool for patient management," the said in a tweet.

"Standardization achievable through equine sera based treatment modality thus stands out as yet another remarkable public health initiative supported by ICMR in the time of COVID-19," it said.

As part of the study, 10 healthy horses were immunized with inactivated SARS-CoV-2 virus and after 21 days of immunization, plasma samples were tested.

The results of the plasma samples indicated presence ofindicated the presence of SARS-Co-V2 specific IgG antibodies as detected in ELISA with neutralizing capacity. The study has not yet been peer-reviewed.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, October 02 2020. 06:39 IST
RECOMMENDED FOR YOU